Lymphoma. Hodgkinlymfomen and non-Hodgkin's disease
Information on current developments in both regular and alternative or complementary treatments and resources for lymphoma - non-Hodgkin's lymphoma and Hodgkin's disease at all stages.
Recent articles in left column more or less in alphabetical order classified
Experiences of cancer patients with complementary approaches can be found by experience stories on our website and there are also some videos of experiences of cancer patients with complementary approaches to see. To click on video button top left of this page. Or visit the website of the SNFK information where movies are shown on complementary approaches to cancer.
Cancer Immunotherapies with lymfklier: Non-Hodgkin and vaccination with BiovaxID is successful and promising approach.
This article is a few hours worked. Lookup, translate, places etc. If you want to support us you can do so through a donation anonymous or not. Any amount is welcome no matter how small. Click here if you want to help us to keep cancer-news online We are an ANBI organization and so your donation is tax-deductible.
11 January 2012:
Interesting to mention is in addition to the information below a summary article of the approach with radio therapy-irradiation in combination with shapes of chemo and immuuntherapeutische resources including Zevalin and Bexxar and Yttrium-90: Radioimmunotherapy or Non-Disease Lymphoma: From the ' Magic Bullets ' to ' Radioactive Magic Bullets '
In the abstract state this, but click on this link for the full study report.
Down state information about immunotherapies with BiovaxID ®. If you click here you can read and see how you as a patient may obtain BiovaxID ® can:
Source: Radioimmunotherapy (RIT) or lymphoma with Zevalin and Bexxar was approved by FDA in 2002 and 2003, respectively, for the treatment of relapsed or refractory follicular CD20 + B-cell non-Hodgkin's lymphoma ´ s. In 2009, Zevalin was also approved for consolidation therapy in patients with follicular non-Disease lymphoma that achieve a partial or complete response to first-line chemotherapy. For follicular lymphoma patients, the overall response and progression-free survival rates have significantly improved since the implementation or ride. The predominant hematological toxicity complication or ride is that is usually manageable. There are ongoing trials to further define the expanding role of RIDE as first line or concomitant therapy in the treatment of lymphoma as well as for certain antibiotic resistant infections and aggressive malignancies. There is also growing interest in the development of newer protocols for increased and more uniform dose delivery resulting in better outcomes and improved patient survival. This review will primarily focus on the role or RIDE in treatment of non-Disease lymphoma, which is established or clinical utility and FDA approved. The mechanism of RIDE, available radionuclides and pharmacokinetics, therapy administration, clinical utility and toxicities, and future directions would be discussed.
september 2001: source: ourown contacts and Pubmed
A visitor to the site I got sent studies below that indicate that this company is very far with the development of a vaccine against non-Hodgkin Lymphomas. Studies show that 90% 7-jaarsgrens follow-up survives without a relapse after vaccination with the addition of GM-GSM, a immuunstimulator, over 90% of the patients with non-Hodgkin's lymphoma associated with a standard chemotherapy treatment die of their non-Hodgkin 's. A very promising and remarkably message that especially for patients with non-Hodgkin 's, but perhaps also for people with other Leukemiablood related cancers such as patients with Waldenström and Kahler , augur can be.
Source: Accentia-website. http://www.businesswire.com/portal/site/google/?ndmViewId=news_view&newsId=20090628005016&newsLang=en (also read schedules etc.)
A short free translation of the main points of English study descriptions below.
In Hsu, et al. 's study at Stanford University researchers by patients were treated with an autologous vaccine against Ig (antigen) of their tumors and observed according to clinical principles. After standard chemotherapy received 41 patients with non-Hodgkin's lymfomen (NHL) a series of injections that the tumor protein antigen (Ig) contained linked to ' keyhole limpet ' (don't know what this means in English).
Note: this prototype vaccine not contained the immuunstimulator GM-CSF. The average duration of the follow-up of all patients was 7.3 years after diagnosis and 5.3 years from the termination of the chemotherapy and start of the vaccination.
Twenty patients (49%) saw an immune response against the original type of their tumor-antigen. Two patients who had ' residual disease ' (cancer research which shows that cancer cells left behind after treatment, so these patients always get a relapse normally), received a complete tumor remission-cancer-disappeared to a result of this immune response. The average duration of no disease progression and survival duration of all 20 patients was significantly longer and better compared with patients who showed no immune response.
32 patients were in a first remission and nine in a successor remission before the vaccination started. An analysis of 32 patients who were in a first remission showed a better clinical outcome for thepatients who showed a specific immune response than those who showed this not. (free of disease progression, 7.9 year over 1.3 years and an average survival from the time after the last chemo treatment exceeded the time of observation of 7 years for non-responsive (non-responders) patients.
, br > The full study results are published in Hsu, JH, Caspar CB, et al. Tumor-specific idiotype vaccines in the treatment of patients with B-cell lymphoma-long term results of a clinical trial. Blood 89 (9): 2416-3135 seen May 1997
Study results of vaccination plus GM-GSF.
The Biovest cancer vaccine (where so GM added to GSF) is an improvement of the prototype vaccine developed at Stanford and has demonstrated very positive results in initial clinical trials. The NCI-National Cancer Institute-tested the use of CM-GSG-iuumstimulator a-keyhole limpet hemocyanin Id as a supplement to the antigen (sorry don't know how to translate into good English). A Phase II study with 20 patients to evaluate the vaccine was published in 1999 by the NCI. The study evaluated the capabilities of the idiotype protein vaccine formula for disadvantaged lymphoma cells Biovest completely destroy at 20 patients who in a homogenous first remission period were caused by chemo. The difference with the previous study with vaccines was that to the prototype of the Stanford vaccine the agents that stimulate medium-GM-granulocyte-monocyte colony-stimulating-GSF-was added. Adding of GM-GSF was based on previous study results, which showed that GM-GSF's have the possibility tumorspecifieke CD8 T-immune cells (immune cells) develop by editing the antigen introduced to increase.
11 patients in the study with demonstrable primary tumor markers (translocations) showed detectable cells in their blood by PCR, a first round of both diagnosis and after standard chemotherapy. The removal of remaining cancer cells in the blood by vaccination is an extremely important difference with the effect of traditional chemotherapy and that a targeted vaccination. Of the 11 vaccinated patients who were tested by a molecular analysis, were only in 3 patients FL-detectable tumor cells. This is very encouraging, since the disease is detectable by this method, even in patients who have gone in a complete clinical remission after other treatments.
The final results are even better. 18 of the 20 patients (90%) showed a continuous clinical remission with an average follow-up of more than 42 months. Tumorspecifieke cytotoxic CD8 and CD4 T-cells were found uniform (at 19 of the 20 patients) treated patients. So vaccination is associated with a permanent removal of lymphoma cells.
This study results vary enormously with the expected gradientThis disease after standard chemotherapy and irradiation, which an average time up to a relapse for FL patients shows of three years, with 90% of the patients die within 7 years after diagnosis to tumorgerelateerde cause. The full study results are published in:
Bendandi M, Gocke CD, et al. Complete molecular remissions induced by patient-specific vaccination plus granulocyte-monocyte colony-stimulating factor against lymphoma. Nature Medicine. 5 (10): 1171-1177. October 1999.
After this encouraging study I and II study results is in January 2000 with a phase III study group of 375 patients. (see also English text for preliminary report thereof).
Source: Accentia-website. http://www.accentia.net/companies/biovestimmunotherapy
The Biovest cancer immunotherapie stems from work begun in 1986 on development of a patient-specific follicular lymphoma (FL) vaccine. The cancer vaccine evokes the power of each patient's immune system and primes it to recognize and eliminate detecting pre-cancerous lymphoma cells, while sparing normal B-cells. In the B-cell lymphoma, vaccine's cancer target, the process is made possible by the presence of a hallmark surface antigen of the cancer cells that is not present in non-detecting pre-cancerous tissue. By priming the immune system with this antigen in the form of an autologous vaccine, the vaccine schizophrenia and a powerful immune response against the detecting pre-cancerous cells that in many cases results in pronounced, complete cancer clearance. Because each dose of Biovest's vaccine is derived from individual patient's detecting pre-cancerous cells, the vaccine is a true targeted, customized therapy. The vaccine's powerful anti-tumor effect vastly exceeds that of non-targeted traditional therapy, as it arises from the immune system's defense cells ' innate ability to selectively target foreign antigens. Most importantly, the immune response triggered by the vaccine against the detecting pre-cancerous tissue is a natural disease-fighting mechanism and has almost none of the side-effects associated with the broad-spectrum chemotherapy and radiation used to traditionally treat this type of lymphoma.
Biovest Immunotherapie-Levy Study Results
In Hsu, et al. 's study at Stanford University, researchers immunized patients with the autologous vaccine against the Ig (antigen) expressed by their tumor and observed their clinical outcomes. After standard chemotherapy, 41 patients with non-Hodgkins Lymphoma (NHL) received a series of infections or tumor protein coupled to keyhole limpet consisting Ig. Note that this prototype vaccine did not include the immune stimulant GM-CSF (see below). The median duration of follow-up for allpatients was 7.3 years from the diagnosis and 5.3 years from the final chemotherapy given before the vaccination.
Twenty patients (49%) generated specific immune responses against the Ig idiotypes of their tumor. Two patients who had residual disease experienced complete tumor regression in association with the development of these immune responses. The median duration of freedom from disease progression and overall survival or all 20 patients mounting an anti-idiotype immune response were significantly prolonged compared to the patients who did not mount an immune response.
Thirty-two patients were in their first remission and nine were in subsequent remissions before beginning vaccine treatments. Analysis of the 32 first remission patients also shows an improved clinical outcome for those patients who mounted a specific immune response compared to those who did not (freedom from progression, 7.9 years v 1.3 years and a median survival from time or last chemotherapy that exceeded the time of observation v 7 years for non-responding patients).
The full study results are published at:
Hsu, JH, Caspar CB, et al. Tumor-specific idiotype vaccines in the treatment of patients with B-cell lymphoma-long term results of a clinical trial. Blood 89 (9): 2416-3135 seen May 1997
Biovest Immunotherapie-Bendandi et al. Study Results or Vaccine + GM-CSF
The Biovest cancer vaccine is an improvement over the prototype vaccine developed at Stanford and it has demonstrated extremely encouraging results in initial clinical trials. The NCI tested the use of an approved immune stimulant, GM-CSF, as an adjunct to the keyhole limpet hemocyanin Id-antigen. A 20-patient Phase II study to evaluate the vaccine was reported by the National Cancer Institute (NCI) in 1999. The study evaluated the ability of the BioVest idiotype protein vaccine formulation to eradicate residual lymphoma cells in 20 patients in a homogeneous, chemotherapy-induced first complete clinical remission. In this trial as opposed to the prototype vaccine developed at Stanford, the difference was patient eligibility and granulocyte-monocyte colony-the addition of stimulating factor (GM-CSF) to the vaccine formulation. The inclusion or GM-CSF was based on previous studies demonstrating GM-you're ability to generate specific CD8 T-cell tumor-immunity by enhancing the processing or introduced antigen.
11 patients in the study with detectable primary tumor markers (translocations), showed detectable cells in their blood by PCR both at diagnosis and following the first round of standard chemotherapy. The vaccine's clearance of these residual cancer cells in the blood is an important distinction between the efficacy of traditional therapy and that of a targeted cancer vaccine. Out of 11 vaccinated patients who were tested by the molecular analysis, FL tumor cells were detectable in only 3 patients. This is extremely encouraging, since the disease is detectable by thismethod even in those patients who go into complete clinical remission after other treatments.
The final study results are even more striking, with 18 or 20 (90%) or the patients demonstrating continuous clinical remission with a median followup or 42 + months. Tumor-specific cytotoxic CD8 + and CD4 + T cells were uniformly found (19 or 20 patients) in the patients treated. Vaccination was thus associated with prolonged clearance or lymphoma cells.
The full study results are published at:
Bendandi M, Gocke CD, et al. Complete molecular remissions induced by patient-specific vaccination plus granulocyte-monocyte colony-stimulating factor against lymphoma. Nature Medicine. 5 (10): 1171-1177. October 1999.
These results contrast with the expected course of the disease after standard chemotherapy and radiation, which shows median relapse time for FL patients or three years, with 90% of patients dying of a tumor-related mortality within 7 years of the date of diagnosis.
Long term Followup and Study Results
Long-term follow-up of these patients in the Phase II was recently completed (summer 2003) and demonstrates in the study patients. Induction or CD4 + T cell response in 100% of patients, induction or CD8 + T cell response in 86% patients (defined by lysis of autologous lymphoma targets), induction of molecular remission in 75% of patients, and most critically, the median time to relapse has now exceeded 7 years since the start of the trials.
Pivotal Phase III
As a result of the promising Phase II results, the FDA and NCI have approved a pivotal Phase III study involving 375 patients. In January 2000, the NCI opened a multi-institutional phase III randomized clinical trial that is scientifically designed to definitively evaluate the question of clinical benefit induced by patient-specific idiotype vaccines in follicular lymphoma patients. Previously untreated follicular lymphoma patients are initially treated with internship advanced a uniform chemotherapy regimen that has produced complete response in virtually all patients to date (84%). Approximately six months after the completion of chemotherapy, patients in complete remission or complete remission unconfirmed are treated with either the experimental tumor-specific vaccine (Id-KLH vaccine + GM-CSF) or the control non-specific vaccine (KLH + GM-CSF).
Patients who attain a CR or complete response unconfirmed (CRu) with a standard chemotherapy regimen or Prednisone, Doxorubicin, Cyclophosphamide uniform, and Etoposide (PACE) chemotherapy are randomized to the experimental tumor-specific vaccination arm (Id-KLH vaccine + GM-CSF) or the control non-specific vaccination arm (KLH + GM-CSF). There is no placebo treatment arm. The randomization is done in a 2: 1 ratio in favor of the specific vaccination arm. Neither the patient, treating physician or anyone directly involved with treating patients on the study is aware of the treatment apatient has been assigned. Patients who remain in CR or CRu, early vaccination approximately 6 months (or whenever a customized vaccine is available, up to a maximum period of 12 months) after the completion of chemotherapy to allow time for immunological recovery. Each patient receives five vaccinations over a period of 6 months subcutaneous.
Study Participation
As of January 2003, 128 patients have been accrued on to the Phase III study. Of the 96 patients that completed chemotherapy, 81 patients (~ 85%) achieved complete remission or molecular complete remission. CR or CRu. Twenty-nine patients have either completed or started the vaccination. The toxicities due to the PACE chemotherapy are generally those related to the chemotherapy agents, including some serious toxicities such as secondary leukemias. The side effects of the vaccine have been mainly local such as erythema, induration and mild tenderness at the injection site or. The vaccine or GM-CSF may cause fever, chills and flu-like symptoms. Bone pain and hypotension have been occasionally observed with GM-CSF. No long-term toxicities or deaths have been associated with the vaccine in the completed phase II study.
Expanded Applications
In addition to forms of non-Hodgkins lymphoma other than the follicular type (FL), the vaccine technology has the potential to offer substantial benefits to other related B-cell derived neoplasms such as multiple myeloma and chronic lymphocytic leukemia. Like non-Hodgkins lymphoma, these neoplasms also express an id on the surface of their tumor cells.
d.d. January 2001:
Below we have got different sides press release. A very promising and remarkably message that especially for patients with non-Hodgkin 's, but perhaps also for people with other Leukemiablood related cancers such as patients with Waldenström and Kahler , augur can be.
A brief translation of the essence of this American message:
In a Phase II study has Dr. Larry w. Kwak, M.D., Ph.d., Senior Investigator at the National Institutes of Health, demonstrated that vaccination with a vaccine grown from own tumor cells in patients with blood related cancers such as non-Hodgkin a lasting remission (non-Hodgkin disappears and no longer back) has caused. 18 of the 20 patients who have been vaccinated with the vaccine are already four years after administration of other cancer. Side effects were minimal or negligible. All participating patients sat with their cancer at an early stage of their cancer was brought by a chemo treatment far back. The National Cancer Institute (NCI) is now in five major hospitals in America on a large scale Phase III study with this car vaccination.
We know that especially in the VU Amsterdam also successful trials have been done with car vaccination in colon cancer and related blood cancers and non-Hodgkin 's. These trials are repeated on a larger scale and persecuted in a number of larger hospitals in Netherlands. For a story about a woman who survived with non-Hodgkin's and only diet and supplementation seems to be cured see the story of Mrs Bruins
The American press release:
Cancer Vaccine Pioneer At NYU To Review Personalized Cancer Vaccines, Pioneering Biotherapies Are At Advanced Trials Stage
NEW YORK--(BUSINESS WIRE)--Jan. 25, 2001--Dr. Larry w. Kwak, M.D., Ph.d., Senior Investigator at the National Institutes of Health, will present published findings related to work on personalized cancer vaccine technologies, at 1 p.m. on Jan. 26, 2001, at The New York University Medical Center (NYU). Specifically, Dr. Kwak will discuss pioneering advances in the field of tumor-specific personalized cancer vaccines, to treat a variety of lethal cancers.
As one example, on Sept. 27, 1999, the National Cancer Institute (NCI)
announced that, for the first time ever, results of a Phase II cancer vaccine
study demonstrated an anti-tumor effect in a small group of patients
vaccinated over a five-year period. NCI researchers reported that 18 or 20
patients vaccinated against this common blood-cell tumor remained in complete remission an average of four years after vaccine therapy began. Prior to vaccination, all of the patients in the Phase II study had minimal disease or were in a chemotherapy-induced first remission.
As a result, NCI launched a large-scale, randomized, Phase III clinical trial
to test theseexperimental cancer vaccines, which are custom-made from
patients ' own tumor cells when in complete remission after chemotherapy. The side effects of the vaccine appear to be minor or non-existent. Its
production requires extremely unique technologies.
NYU is considering an opportunity to participate in, and play a pivotal role
in, this national Phase III trial. Currently, cancer vaccine trials are in
Phase III trials at five leading medical centers: Northwestern University
Medical School, University of Pennsylvania, Duke University, the Moffitt
Cancer Center at University of Southern Florida, and at the National Cancer
Institute in Bethesda, Maryland.
In the year 2001, an estimated 54,900 people are expected to be diagnosed with non-Disease lymphoma. Biovest International is currently producing the aforementioned cancer vaccines for the national Phase III trial.
